Incruse ellipta and Middle insomnia - a phase IV clinical study of FDA data


Middle insomnia is found among people who take Incruse ellipta, especially for people who are female, 60+ old.

The phase IV clinical study analyzes which people take Incruse ellipta and have Middle insomnia. It is created by eHealthMe based on reports of 6,898 people who have side effects when taking Incruse ellipta from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Oct, 03, 2022

6,898 people reported to have side effects when taking Incruse ellipta.
Among them, 34 people (0.49%) have Middle insomnia.

What is Incruse ellipta?

Incruse ellipta has active ingredients of umeclidinium bromide. eHealthMe is studying from 6,931 Incruse ellipta users for its effectiveness, alternative drugs and more.

What is Middle insomnia?

Middle insomnia (difficulty returning to sleep after awakening either in the middle of the night) is found to be associated with 1,478 drugs and 941 conditions by eHealthMe.

Number of Incruse ellipta and Middle insomnia reports submitted per year:

Could Incruse ellipta cause Middle insomnia?

Gender of people who have Middle insomnia when taking Incruse ellipta *:

  • female: 56.25 %
  • male: 43.75 %

Age of people who have Middle insomnia when taking Incruse ellipta *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 13.04 %
  • 40-49: 0.0 %
  • 50-59: 26.09 %
  • 60+: 60.87 %

Common drugs people take besides Incruse ellipta *:

  1. Xolair: 15 people, 44.12%
  2. Breo Ellipta: 12 people, 35.29%
  3. Ventolin: 12 people, 35.29%
  4. Singulair: 11 people, 32.35%
  5. Advair Hfa: 10 people, 29.41%
  6. Symbicort: 9 people, 26.47%
  7. Dupixent: 5 people, 14.71%
  8. Albuterol: 4 people, 11.76%
  9. Aspirin: 4 people, 11.76%
  10. Spiriva: 4 people, 11.76%

Common side effects people have besides Middle insomnia *:

  1. Breathing Difficulty: 16 people, 47.06%
  2. Asthma: 15 people, 44.12%
  3. Cough: 13 people, 38.24%
  4. Wheezing (a high-pitched whistling sound made while you breath): 12 people, 35.29%
  5. Productive Cough: 8 people, 23.53%
  6. Obstructive Airways Disorder (a progressive disease that makes it hard to breathe): 8 people, 23.53%
  7. Chest Pain: 7 people, 20.59%
  8. Malaise (a feeling of general discomfort or uneasiness): 7 people, 20.59%
  9. Lung Hyperinflation (inspiration of more than normal): 6 people, 17.65%
  10. Fatigue (feeling of tiredness): 6 people, 17.65%

Common conditions people have *:

  1. Asthma: 23 people, 67.65%
  2. Depression: 3 people, 8.82%
  3. Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 3 people, 8.82%
  4. Ovarian Cancer (cancer of ovary): 2 people, 5.88%
  5. Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 2 people, 5.88%
  6. Vitamin B12 Deficiency: 2 people, 5.88%
  7. Emphysema (chronic respiratory disease - over inflation of the air sacs (alveoli) in the lungs): 2 people, 5.88%
  8. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 2.94%
  9. Breathing Difficulty: 1 person, 2.94%
  10. Dyslipidaemia (abnormal amount of lipids): 1 person, 2.94%

* Approximation only. Some reports may have incomplete information.

Do you take Incruse ellipta and have Middle insomnia?

Check whether Middle insomnia is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Middle insomnia and when was it recovered:

Expand to all the drugs that have ingredients of umeclidinium bromide:

Alternative drugs to, pros and cons of Incruse ellipta:

Common Incruse ellipta side effects:

Browse all side effects of Incruse ellipta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Middle insomnia treatments and more:

COVID vaccines that are related to Middle insomnia:

Common drugs associated with Middle insomnia:

All the drugs that are associated with Middle insomnia:

Common conditions associated with Middle insomnia:

All the conditions that are associated with Middle insomnia:

How the study uses the data?

The study uses data from the FDA. It is based on umeclidinium bromide (the active ingredients of Incruse ellipta) and Incruse ellipta (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: